Air pollution threatens the respiratory health of patients with interstitial lung disease (ILD). High-efficiency air purifiers, featuring easy operation and excellent particulate matter removal efficiency, have been shown in previous studies to potentially delay lung function deterioration and reduce acute exacerbation risk in respiratory disease patients. This randomized crossover study employs air purifiers to filter indoor gaseous pollutants, allergens, and other contaminants, aiming to alleviate respiratory irritation, improve daily life comfort, and enhance overall health status in ILD patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Symptom Improvement-related Indicators (e.g., Improvement in Respiratory Symptom Score)
Timeframe: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Pulmonary Function Indicators (e.g., Pulmonary Diffusing Capacity)
Timeframe: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Quality of Life Indicators (e.g., CAT Score)
Timeframe: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)
Blood Sample Indicators (e.g., Concentration of Interleukin-8)
Timeframe: Baseline (before intervention), Week 2 (end of first phase), Week 6 (end of second phase)